Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 6/20 | 0.73 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 7/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708016 | 1.00 | ALOX5AP (0.73) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL3002644 | 0.91 | ALOX5AP (0.66) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL708386 | 0.90 | ALOX5AP (0.90) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL708385 | 0.90 | ALOX5AP (0.90) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL9924147 | 0.89 | ALOX5AP (0.73) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL9924148 | 0.88 | ALOX5AP (0.71) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL707244 | 0.85 | ALOX5AP (0.70) | ALOX5APADAMTS4MAPK14SMOCYP3A4 | |
| SCHEMBL9924152 | 0.85 | ALOX5AP (0.65) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL480273 | 0.84 | ALOX5AP (1.00) | ALOX5APADAMTS4MAPK14SMONPC1 | |
| SCHEMBL480478 | 0.83 | ALOX5AP (0.80) | ALOX5APADAMTS4MAPK14SMONPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | claimed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | claimed |
| EP-2013174-A2 | DIARYL SUBSTITUTED ALKANES | Merck & Co., Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007120574-A2 | DIARYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885ADAMTS4 1701/4885MAPK14 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.